دورية أكاديمية
أعرض في EDS

Injectable Shear-Thinning Hydrogels with Sclerosing and Matrix Metalloproteinase Modulatory Properties for the Treatment of Vascular Malformations.

التفاصيل البيبلوغرافية
العنوان: Injectable Shear-Thinning Hydrogels with Sclerosing and Matrix Metalloproteinase Modulatory Properties for the Treatment of Vascular Malformations.
المؤلفون: Zehtabi F; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Gangrade A; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Tseng K; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States.; Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, California 90007, United States., Haghniaz R; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Abasgholizadeh R; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Montazerian H; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States.; Department of Bioengineering, University of California, Los Angeles, Los Angeles, California 90095, United States.; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, California 90095, United States., Khorsandi D; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Bahari J; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Ahari A; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Mohaghegh N; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Kouchehbaghi NH; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States.; Department of Textile Engineering, Amirkabir University of Technology (Tehran Polytechnic), Hafez Avenue, 1591634311 Tehran, Iran., Mandal K; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Mecwan M; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Rashad A; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., de Barros NR; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Byun Y; College of Pharmacy, Korea University, Sejong 30019, Republic of Korea., Ermis M; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States., Kim HJ; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States.; College of Pharmacy, Korea University, Sejong 30019, Republic of Korea.; Vellore Institute of Technology (VIT), Vellore, India, 632014., Khademhosseini A; Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, United States.
المصدر: Advanced functional materials [Adv Funct Mater] 2023 Dec 15; Vol. 33 (51). Date of Electronic Publication: 2023 Sep 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101190390 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1616-301X (Print) Linking ISSN: 1616301X NLM ISO Abbreviation: Adv Funct Mater Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Weinheim, Germany : Wiley-VCH, c2001-
مستخلص: Sac embolization of abdominal aortic aneurysms (AAAs) remains clinically limited by endoleak recurrences. These recurrences are correlated with recanalization due to the presence of endothelial lining and matrix metalloproteinases (MMPs)-mediated aneurysm progression. This study incorporated doxycycline (DOX), a well-known sclerosant and MMPs inhibitor, into a shear-thinning biomaterial (STB)-based vascular embolizing hydrogel. The addition of DOX was expected to improve embolizing efficacy while preventing endoleaks by inhibiting MMP activity and promoting endothelial removal. The results showed that STBs containing 4.5% w/w silicate nanoplatelet and 0.3% w/v of DOX were injectable and had a 2-fold increase in storage modulus compared to those without DOX. STB-DOX hydrogels also reduced clotting time by 33% compared to untreated blood. The burst release of DOX from the hydrogels showed sclerosing effects after 6 h in an ex vivo pig aorta model. Sustained release of DOX from hydrogels on endothelial cells showed MMP inhibition ( ca . an order of magnitude larger than control groups) after 7 days. The hydrogels successfully occluded a patient-derived abdominal aneurysm model at physiological blood pressures and flow rates. The sclerosing and MMP inhibition characteristics in the engineered multifunctional STB-DOX hydrogels may provide promising opportunities for the efficient embolization of aneurysms in blood vessels.
Competing Interests: Conflict of Interest A.K. is the Co-founder of a start-up, Obsidio, Inc., which is based on shear-thinning embolic materials. Now Obsidio is a part of Boston Scientific.
References: Cardiovasc Intervent Radiol. 2017 Apr;40(4):576-584. (PMID: 28078379)
Curr Opin Hematol. 2016 May;23(3):253-9. (PMID: 27055047)
J Clin Med. 2023 Jan 06;12(2):. (PMID: 36675413)
Cardiovasc Intervent Radiol. 2014 Jun;37(3):613-22. (PMID: 23903786)
J Vasc Surg. 2020 Dec;72(6):1960-1967. (PMID: 32471739)
Acta Biomater. 2017 Dec;64:94-105. (PMID: 28927932)
Macromol Biosci. 2023 Jan;23(1):e2200333. (PMID: 36287084)
Bioact Mater. 2022 Nov 24;23:314-327. (PMID: 36439081)
Circ Res. 2019 Feb 15;124(4):607-618. (PMID: 30763207)
Prog Mol Biol Transl Sci. 2017;147:239-265. (PMID: 28413030)
Adv Sci (Weinh). 2022 Jan;9(3):e2103608. (PMID: 34821070)
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6485-90. (PMID: 24733925)
Blood Transfus. 2011 May;9 Suppl 2:s3-8. (PMID: 21839029)
Ann Vasc Surg. 2006 Mar;20(2):228-36. (PMID: 16572291)
J Endovasc Ther. 2011 Oct;18(5):686-96. (PMID: 21992641)
Br J Surg. 2013 Sep;100(10):1262-70. (PMID: 23939840)
Cell Adh Migr. 2014;8(2):158-64. (PMID: 25422846)
Cardiovasc Intervent Radiol. 2013 Oct;36(5):1288-95. (PMID: 23397186)
Eur J Vasc Endovasc Surg. 2008 May;35(5):580-4. (PMID: 18226564)
ACS Appl Mater Interfaces. 2022 Sep 28;14(38):42852-42863. (PMID: 36121372)
JACC Basic Transl Sci. 2023 Feb 27;8(2):171-173. (PMID: 36908666)
J Clin Invest. 2002 Sep;110(5):625-32. (PMID: 12208863)
Semin Intervent Radiol. 2010 Dec;27(4):391-9. (PMID: 22550381)
J Cell Commun Signal. 2016 Dec;10(4):347-354. (PMID: 27619687)
Circulation. 2008 Apr 8;117(14):1883-9. (PMID: 18391122)
ACS Nano. 2014 Oct 28;8(10):9833-42. (PMID: 25221894)
J Vasc Surg. 2012 Jan;55(1):33-40. (PMID: 22056249)
Sci Transl Med. 2016 Nov 16;8(365):365ra156. (PMID: 27856795)
J Vasc Surg. 2005 Aug;42(2):321-8. (PMID: 16102634)
Contrast Media Mol Imaging. 2021 Apr 27;2021:9999847. (PMID: 34007253)
J Vasc Surg. 2003 Jan;37(1):8-15. (PMID: 12514572)
Nanoscale. 2022 Jan 6;14(2):350-360. (PMID: 34908077)
Contemp Clin Trials. 2016 May;48:91-8. (PMID: 27018941)
J Biomed Mater Res B Appl Biomater. 2016 Nov;104(8):1551-1562. (PMID: 26284313)
Br J Cancer. 2016 Sep 6;115(6):703-6. (PMID: 27187685)
J Vasc Interv Radiol. 2008 Jul;19(7):1070-8. (PMID: 18589322)
Sci Rep. 2023 Jan 2;13(1):14. (PMID: 36593362)
J Cell Biol. 2015 Mar 16;208(6):821-38. (PMID: 25753039)
Int J Mol Sci. 2022 Sep 21;23(19):. (PMID: 36232377)
Adv Dent Res. 1998 Nov;12(2):114-8. (PMID: 9972133)
معلومات مُعتمدة: R01 CA257558 United States CA NCI NIH HHS; R01 DK130566 United States DK NIDDK NIH HHS; R01 HL137193 United States HL NHLBI NIH HHS; R01 HL140951 United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: drug delivery; embolization; endothelial dysfunction; shear thinning biomaterial; silicate nanoplatelet
تواريخ الأحداث: Date Created: 20240401 Latest Revision: 20240403
رمز التحديث: 20240403
مُعرف محوري في PubMed: PMC10977963
DOI: 10.1002/adfm.202305880
PMID: 38558868
قاعدة البيانات: MEDLINE
الوصف
تدمد:1616-301X
DOI:10.1002/adfm.202305880